Inventor
Matthew W. Martin
Inventor
Arlington, MA, US
Overview
Patents· 54 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07DHeterocyclic compounds29%
A61KPreparations for medical, dental or toiletry purposes24%
Y02ATechnologies for adaptation to climate change15%
C07CAcyclic or carbocyclic compounds3%
C04BLime, magnesia1%
C07BGeneral methods of organic chemistry1%
PatentTitleYear
10,875,848Inhibiting fatty acid synthase (FASN)202010,829,4623-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202010,829,4613-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202010,822,3163-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202010,800,750Compounds and compositions for inhibition of FASN202010,793,554Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone202010,703,764Benzopiperazine compositions as BET bromodomain inhibitors202010,611,750Tetrahydroquinoline compositions as bet bromodomain inhibitors202010,538,496Methods using HDAC11 inhibitors202010,513,5013-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,508,077Alpha-cinnamide compounds and compositions as HDAC8 inhibitors201910,508,088Methods using HDAC11 inhibitors201910,501,4243-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,494,3513-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,494,3543-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,494,3533-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,494,3523-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,479,7723-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,472,342Compounds and compositions for inhibition of FASN201910,472,3373-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,464,9093-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,464,9103-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,457,655Compounds and compositions for inhibition of FASN201910,457,6523-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,450,2843-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,450,2833-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,450,286Compounds and compositions for inhibition of FASN201910,442,7763-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,428,0313-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,421,7313-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,421,7323-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,414,7383-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,399,951Compounds and compositions for inhibition of FASN201910,377,769Benzopiperazine compositions as BET bromodomain inhibitors201910,377,7263-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,336,722Tetrahydroquinoline compositions as BET bromodomain inhibitors201910,266,487Alpha-cinnamide compounds and compositions as HDAC8 inhibitors201910,239,8453-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,214,5013-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,214,5003-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors201910,112,9153-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors20189,745,253'Alpha-cinnamide compounds and compositions as HDAC8 inhibitors'20179,422,281'Benzopiperazine compositions as BET bromodomain inhibitors'20169,388,161'Tetrahydroquinoline compositions as BET bromodomain inhibitors'20169,340,549'Oxazolidinone compounds and derivatives thereof'20168,492,404'Bis-aryl amide compounds and methods of use'20138,178,557'Compounds and methods of use'20127,795,254'Benzomorpholine derivatives and methods of use'20107,776,857'Aurora kinase modulators and method of use'20107,776,869'Heteroaryl-substituted alkyne compounds and method of use'20107,754,717'Bis-aryl amide compounds and methods of use'20107,674,907'Furanopyridine derivatives and methods of use'20107,442,698'Substituted heterocyclic compounds and methods of use'20087,435,823'Compounds and methods of use'2008Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2008–2016Patents assigned to AMGEN INC (10)· patent assignee history
2008–2010Based in Cambridge, MA, US· patent location history
2010–2020Based in Arlington, MA, US· patent location history
2012–2013Patents assigned to MARTIN MATTHEW W (2)· patent assignee history
2012–2013Patents assigned to MCGOWAN DAVID C (2)· patent assignee history
2016–2020Patents assigned to FORMA THERAPEUTICS INC (41)· patent assignee history
2020Patents assigned to VALO EARLY DISCOVERY INC (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| FORMA THERAPEUTICS INC | 41 | 2016–2020 |
| AMGEN INC | 10 | 2008–2016 |
| VALO EARLY DISCOVERY INC | 3 | 2020 |
| MARTIN MATTHEW Wself | 2 | 2012–2013 |
| MCGOWAN DAVID C | 2 | 2012–2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| Arlington, Massachusetts, US | 49 | 2010–2020 |
| Cambridge, Massachusetts, US | 5 | 2008–2010 |